By inhibiting the MR and subsequently downregulating the expression of Gnαi2, finerenone treatment significantly suppressed the over-activation of the complement C5a-C5aR1 axis and associated chemotaxis damages, thereby alleviating kidney damages in DN. This evidence concerns the gene GNAI2 and liver dysplastic nodule.